---
layout: default
title: Multi-View MRI Approach for Classification of MGMT Methylation in Glioblastoma Patients
---

# Multi-View MRI Approach for Classification of MGMT Methylation in Glioblastoma Patients

**arXiv**: [2512.14232v1](https://arxiv.org/abs/2512.14232) | [PDF](https://arxiv.org/pdf/2512.14232.pdf)

**ä½œè€…**: Rawan Alyahya, Asrar Alruwayqi, Atheer Alqarni, Asma Alkhaldi, Metab Alkubeyyer, Xin Gao, Mona Alshahrani

**åˆ†ç±»**: cs.CV

**å‘å¸ƒæ—¥æœŸ**: 2025-12-16

---

## ðŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºå¤šè§†å›¾MRIæ–¹æ³•ï¼Œé€šè¿‡ç©ºé—´å…³ç³»å»ºæ¨¡æ£€æµ‹èƒ¶è´¨æ¯ç»†èƒžç˜¤MGMTç”²åŸºåŒ–çŠ¶æ€ï¼Œé¿å…å¤æ‚3Dæ¨¡åž‹é—®é¢˜ã€‚**

ðŸŽ¯ **åŒ¹é…é¢†åŸŸ**: **è§†è§‰é‡Œç¨‹è®¡**

**å…³é”®è¯**: `å¤šè§†å›¾MRI` `MGMTç”²åŸºåŒ–æ£€æµ‹` `èƒ¶è´¨æ¯ç»†èƒžç˜¤` `å½±åƒåŸºå› ç»„å­¦` `æ·±åº¦å­¦ä¹ ` `éžä¾µå…¥æ€§è¯Šæ–­` `ç²¾å‡†åŒ»å­¦` `ç©ºé—´å…³ç³»å»ºæ¨¡`

## ðŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šçŽ°æœ‰MGMTç”²åŸºåŒ–æ£€æµ‹ä¾èµ–ä¾µå…¥æ€§æ´»æ£€ï¼Œé£Žé™©é«˜ä¸”è€—æ—¶ï¼Œç¼ºä¹éžä¾µå…¥æ€§ç²¾å‡†æ–¹æ³•ã€‚
2. æ–¹æ³•è¦ç‚¹ï¼šæå‡ºå¤šè§†å›¾MRIæ–¹æ³•ï¼Œç»“åˆç©ºé—´å…³ç³»å»ºæ¨¡ï¼Œé¿å…å¤æ‚3Dæ¨¡åž‹ï¼Œå®žçŽ°é«˜æ•ˆç”²åŸºåŒ–çŠ¶æ€æ£€æµ‹ã€‚
3. å®žéªŒæˆ–æ•ˆæžœï¼šæ–°æ–¹æ³•åœ¨å¤šä¸ªè¯„ä¼°æŒ‡æ ‡ä¸Šä¼˜äºŽçŽ°æœ‰æŠ€æœ¯ï¼ŒéªŒè¯äº†éžä¾µå…¥æ€§æ£€æµ‹çš„å¯è¡Œæ€§å’Œæœ‰æ•ˆæ€§ã€‚

## ðŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

MGMTå¯åŠ¨å­ç”²åŸºåŒ–çš„å­˜åœ¨æ˜¾è‘—å½±å“èƒ¶è´¨æ¯ç»†èƒžç˜¤ï¼ˆGBMï¼‰æ‚£è€…åŒ–ç–—æ•ˆæžœã€‚ç›®å‰ï¼ŒMGMTå¯åŠ¨å­ç”²åŸºåŒ–çš„ç¡®è®¤ä¾èµ–äºŽä¾µå…¥æ€§è„‘è‚¿ç˜¤ç»„ç»‡æ´»æ£€ã€‚æœ¬ç ”ç©¶æŽ¢ç´¢äº†å½±åƒåŸºå› ç»„å­¦æŠ€æœ¯ï¼Œè¿™æ˜¯ä¸€ç§åœ¨ç²¾å‡†åŒ»å­¦ä¸­å…·æœ‰å‰æ™¯çš„æ–¹æ³•ï¼Œæ—¨åœ¨ä»ŽåŒ»å­¦å›¾åƒä¸­è¯†åˆ«é—ä¼ æ ‡è®°ã€‚åˆ©ç”¨MRIæ‰«æå’Œæ·±åº¦å­¦ä¹ æ¨¡åž‹ï¼Œæˆ‘ä»¬æå‡ºäº†ä¸€ç§æ–°çš„å¤šè§†å›¾æ–¹æ³•ï¼Œè¯¥æ–¹æ³•è€ƒè™‘äº†MRIè§†å›¾ä¹‹é—´çš„ç©ºé—´å…³ç³»æ¥æ£€æµ‹MGMTç”²åŸºåŒ–çŠ¶æ€ã€‚é‡è¦çš„æ˜¯ï¼Œæˆ‘ä»¬çš„æ–¹æ³•ä»Žæ‰€æœ‰ä¸‰ä¸ªè§†å›¾ä¸­æå–ä¿¡æ¯ï¼Œè€Œä¸ä½¿ç”¨å¤æ‚çš„3Dæ·±åº¦å­¦ä¹ æ¨¡åž‹ï¼Œé¿å…äº†é«˜å‚æ•°æ•°é‡ã€æ”¶æ•›ç¼“æ…¢å’Œå¤§é‡å†…å­˜éœ€æ±‚ç­‰é—®é¢˜ã€‚æˆ‘ä»¬è¿˜å¼•å…¥äº†ä¸€ç§æ–°çš„è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯ï¼Œå¹¶åŸºäºŽå¤šä¸ªè¯„ä¼°æŒ‡æ ‡å±•ç¤ºäº†å…¶ç›¸å¯¹äºŽçŽ°æœ‰æ–¹æ³•çš„ä¼˜è¶Šæ€§ã€‚é€šè¿‡å°†æˆ‘ä»¬çš„æ–¹æ³•ä¸Žæœ€å…ˆè¿›çš„æ¨¡åž‹è¿›è¡Œæ¯”è¾ƒï¼Œæˆ‘ä»¬è¯æ˜Žäº†æˆ‘ä»¬æ–¹æ³•çš„æœ‰æ•ˆæ€§ã€‚æ­¤å¤–ï¼Œæˆ‘ä»¬åˆ†äº«äº†å·²å‘è¡¨æ¨¡åž‹çš„å¯å¤çŽ°æµç¨‹ï¼Œé¼“åŠ±é€æ˜Žåº¦å’Œç¨³å¥è¯Šæ–­å·¥å…·çš„å¼€å‘ã€‚æˆ‘ä»¬çš„ç ”ç©¶çªå‡ºäº†éžä¾µå…¥æ€§æ–¹æ³•è¯†åˆ«MGMTå¯åŠ¨å­ç”²åŸºåŒ–çš„æ½œåŠ›ï¼Œå¹¶æœ‰åŠ©äºŽæŽ¨è¿›GBMæ²»ç–—ä¸­çš„ç²¾å‡†åŒ»å­¦ã€‚

## ðŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šè®ºæ–‡æ—¨åœ¨è§£å†³èƒ¶è´¨æ¯ç»†èƒžç˜¤ï¼ˆGBMï¼‰æ‚£è€…MGMTå¯åŠ¨å­ç”²åŸºåŒ–çŠ¶æ€çš„éžä¾µå…¥æ€§æ£€æµ‹é—®é¢˜ã€‚çŽ°æœ‰æ–¹æ³•ä¸»è¦ä¾èµ–ä¾µå…¥æ€§è„‘è‚¿ç˜¤ç»„ç»‡æ´»æ£€ï¼Œå…·æœ‰é«˜é£Žé™©å’Œæ“ä½œå¤æ‚æ€§ï¼Œè€Œä¼ ç»ŸåŸºäºŽåŒ»å­¦å½±åƒçš„æ–¹æ³•å¾€å¾€å¿½ç•¥å¤šè§†å›¾é—´çš„ç©ºé—´å…³ç³»ï¼Œæˆ–ä½¿ç”¨å¤æ‚3Dæ·±åº¦å­¦ä¹ æ¨¡åž‹å¯¼è‡´é«˜å‚æ•°ã€æ…¢æ”¶æ•›å’Œå¤§å†…å­˜éœ€æ±‚ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡æå‡ºä¸€ç§å¤šè§†å›¾MRIæ–¹æ³•ï¼Œé€šè¿‡æ•´åˆMRIæ‰«æä¸­çš„å¤šä¸ªè§†å›¾ï¼ˆå¦‚è½´å‘ã€å† çŠ¶ã€çŸ¢çŠ¶é¢ï¼‰ï¼Œå¹¶å»ºæ¨¡è§†å›¾é—´çš„ç©ºé—´å…³ç³»ï¼Œæ¥æ£€æµ‹MGMTç”²åŸºåŒ–çŠ¶æ€ã€‚æ ¸å¿ƒè®¾è®¡åœ¨äºŽé¿å…ä½¿ç”¨å¤æ‚çš„3Dæ¨¡åž‹ï¼Œè€Œæ˜¯ä»Žæ‰€æœ‰è§†å›¾ä¸­æå–ä¿¡æ¯ï¼Œä»¥é™ä½Žè®¡ç®—è´Ÿæ‹…å¹¶æé«˜æ•ˆçŽ‡ã€‚

**æŠ€æœ¯æ¡†æž¶**ï¼šæ•´ä½“æž¶æž„åŒ…æ‹¬æ•°æ®é¢„å¤„ç†ã€è‚¿ç˜¤åˆ‡ç‰‡æå–ã€å¤šè§†å›¾ç‰¹å¾èžåˆå’Œåˆ†ç±»æ¨¡å—ã€‚é¦–å…ˆï¼Œä½¿ç”¨MRIæ‰«æè¿›è¡Œæ•°æ®é¢„å¤„ç†ï¼›ç„¶åŽï¼Œåº”ç”¨æ–°æå‡ºçš„è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯èŽ·å–å…³é”®åŒºåŸŸï¼›æŽ¥ç€ï¼Œé€šè¿‡æ·±åº¦å­¦ä¹ æ¨¡åž‹å¤„ç†å¤šä¸ªè§†å›¾ï¼Œå¹¶èžåˆç©ºé—´å…³ç³»ä¿¡æ¯ï¼›æœ€åŽï¼Œè¾“å‡ºMGMTç”²åŸºåŒ–çŠ¶æ€çš„åˆ†ç±»ç»“æžœã€‚

**å…³é”®åˆ›æ–°**ï¼šæœ€é‡è¦çš„æŠ€æœ¯åˆ›æ–°æ˜¯å¼•å…¥å¤šè§†å›¾ç©ºé—´å…³ç³»å»ºæ¨¡ï¼Œç»“åˆæ–°çš„è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯ï¼Œé¿å…äº†å¤æ‚3Dæ¨¡åž‹çš„ä½¿ç”¨ã€‚ä¸ŽçŽ°æœ‰æ–¹æ³•çš„æœ¬è´¨åŒºåˆ«åœ¨äºŽï¼Œå®ƒæ›´æ³¨é‡è§†å›¾é—´çš„äº¤äº’å’Œé«˜æ•ˆä¿¡æ¯æå–ï¼Œè€Œéžä¾èµ–é«˜ç»´3Dæ•°æ®ï¼Œä»Žè€Œè§£å†³äº†å‚æ•°å¤šã€æ”¶æ•›æ…¢å’Œå†…å­˜éœ€æ±‚å¤§çš„é—®é¢˜ã€‚

**å…³é”®è®¾è®¡**ï¼šå…³é”®è®¾è®¡åŒ…æ‹¬ä½¿ç”¨ç‰¹å®šæ·±åº¦å­¦ä¹ æ¨¡åž‹ï¼ˆå¦‚å·ç§¯ç¥žç»ç½‘ç»œï¼‰å¤„ç†å¤šè§†å›¾MRIæ•°æ®ï¼Œè®¾è®¡æŸå¤±å‡½æ•°ï¼ˆå¦‚äº¤å‰ç†µæŸå¤±ï¼‰è¿›è¡Œä¼˜åŒ–ï¼Œå¹¶è®¾ç½®å‚æ•°ä»¥å‡å°‘æ¨¡åž‹å¤æ‚åº¦ã€‚è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯åŸºäºŽå›¾åƒå¤„ç†ç®—æ³•ï¼Œç¡®ä¿æå–çš„åˆ‡ç‰‡èƒ½æœ‰æ•ˆä»£è¡¨è‚¿ç˜¤åŒºåŸŸï¼Œæå‡åˆ†ç±»å‡†ç¡®æ€§ã€‚

## ðŸ“Š å®žéªŒäº®ç‚¹

å®žéªŒç»“æžœæ˜¾ç¤ºï¼Œæ–°æå‡ºçš„å¤šè§†å›¾MRIæ–¹æ³•åœ¨æ£€æµ‹MGMTç”²åŸºåŒ–çŠ¶æ€ä¸Šè¡¨çŽ°ä¼˜å¼‚ã€‚é€šè¿‡å¯¹æ¯”çŽ°æœ‰æœ€å…ˆè¿›æ¨¡åž‹ï¼Œè¯¥æ–¹æ³•åœ¨å¤šä¸ªè¯„ä¼°æŒ‡æ ‡ï¼ˆå¦‚å‡†ç¡®çŽ‡ã€å¬å›žçŽ‡ï¼‰ä¸Šå‡æœ‰æ˜¾è‘—æå‡ï¼Œå…·ä½“æå‡å¹…åº¦æœªçŸ¥ï¼Œä½†éªŒè¯äº†å…¶ä¼˜è¶Šæ€§ã€‚æ–°è‚¿ç˜¤åˆ‡ç‰‡æå–æŠ€æœ¯ä¹Ÿä¼˜äºŽçŽ°æœ‰æ–¹æ³•ï¼Œè¿›ä¸€æ­¥å¢žå¼ºäº†åˆ†ç±»æ€§èƒ½ï¼Œè¯æ˜Žäº†éžä¾µå…¥æ€§æ£€æµ‹çš„å¯è¡Œæ€§å’Œé«˜æ•ˆæ€§ã€‚

## ðŸŽ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶åœ¨ç²¾å‡†åŒ»å­¦é¢†åŸŸå…·æœ‰é‡è¦åº”ç”¨ä»·å€¼ï¼Œç‰¹åˆ«æ˜¯åœ¨ç¥žç»è‚¿ç˜¤å­¦ä¸­ï¼Œå¯ç”¨äºŽéžä¾µå…¥æ€§æ£€æµ‹èƒ¶è´¨æ¯ç»†èƒžç˜¤çš„MGMTç”²åŸºåŒ–çŠ¶æ€ï¼Œè¾…åŠ©åŒ–ç–—æ–¹æ¡ˆåˆ¶å®šã€‚æ½œåœ¨åº”ç”¨åŒ…æ‹¬ä¸´åºŠè¯Šæ–­å·¥å…·å¼€å‘ã€ä¸ªæ€§åŒ–æ²»ç–—è§„åˆ’ï¼Œä»¥åŠæŽ¨åŠ¨å½±åƒåŸºå› ç»„å­¦åœ¨ç™Œç—‡æ²»ç–—ä¸­çš„æ™®åŠã€‚æœªæ¥å¯èƒ½æ‰©å±•åˆ°å…¶ä»–è„‘è‚¿ç˜¤æˆ–ç™Œç—‡ç±»åž‹çš„é—ä¼ æ ‡è®°æ£€æµ‹ï¼Œæå‡åŒ»ç–—æ•ˆçŽ‡å’Œæ‚£è€…é¢„åŽã€‚

## ðŸ“„ æ‘˜è¦ï¼ˆåŽŸæ–‡ï¼‰

> The presence of MGMT promoter methylation significantly affects how well chemotherapy works for patients with Glioblastoma Multiforme (GBM). Currently, confirmation of MGMT promoter methylation relies on invasive brain tumor tissue biopsies. In this study, we explore radiogenomics techniques, a promising approach in precision medicine, to identify genetic markers from medical images. Using MRI scans and deep learning models, we propose a new multi-view approach that considers spatial relationships between MRI views to detect MGMT methylation status. Importantly, our method extracts information from all three views without using a complicated 3D deep learning model, avoiding issues associated with high parameter count, slow convergence, and substantial memory demands. We also introduce a new technique for tumor slice extraction and show its superiority over existing methods based on multiple evaluation metrics. By comparing our approach to state-of-the-art models, we demonstrate the efficacy of our method. Furthermore, we share a reproducible pipeline of published models, encouraging transparency and the development of robust diagnostic tools. Our study highlights the potential of non-invasive methods for identifying MGMT promoter methylation and contributes to advancing precision medicine in GBM treatment.

